



(I)

wherein either R_1 and R_2 are individually selected from the group consisting of hydrogen, hydroxyl, alkyl and cycloalkyl of up to 8 carbon atoms optionally interrupted by oxygen and optionally substituted by a member selected from the group consisting of




are individually hydrogen or alkyl of 1 to 8 carbon atoms or a and b can optionally form with the nitrogen atom a heterocycle optionally containing at least one additional heteroatom, or R_1 forms with the endocyclic carbon atom carrying




the group consisting of oxygen, $-\text{NH}-$ or $-\text{N-alkyl}$ of 1 to 8 carbon atoms and Ra is selected from the group consisting of hydrogen,

alkyl or cycloalkyl of up to 8 carbon atoms optionally substituted by at least one member of the group consisting of halogen, -OH, -CO₂H, -CO₂alk, and



a' and b' are hydrogen or alkyl of 1 to 8 carbon atoms or a' and b' can form a heterocycle optionally containing at least one additional heteroatom or heterocycle containing at least one heteroatom or R₂ is











in which d, e, f and g are hydrogen or alkyl of 1 to 8 carbon atoms, f and g can also be acyl of up to 8 carbon atoms, and e and f can also form a ring optionally containing at least one heteroatom,

R₃ is selected from the group consisting of hydrogen, methyl and hydroxyl,


R₄ is hydrogen or hydroxyl,

R is selected from the group consisting of





and



)

T is selected from the group consisting of hydrogen, methyl, $-\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{CN}$, $-(\text{CH}_2)_2\text{NH}_2$ and $-(\text{CH}_2)\text{Nalk}^+\text{X}^-$, X is halogen and alk is alkyl of up to 8 carbon atoms,
Y is selected from the group consisting of hydrogen, hydroxyl, halogen and OSO_3H and a salt thereof,
W is hydrogen or $-\text{OH}$,
Z is hydrogen or methyl and a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Claim 2 (amended) A compound of claim 1 in which T is hydrogen.

Claim 3 (amended) A compound of claim 1 in which W is hydrogen.

Claim 4 (amended) A compound of claim 1 in which Z is methyl.





Claim 5 (amended) A compound of claim 1 in which Y is hydrogen.

Claim 6 (amended) A compound of claim 1 in which R_3 is methyl.


Claim 7 (amended) A compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (amended) A compound of claim 1 in which R is

selected from the group consisting of




and




Claim 9 (amended) A compound of claim 1 in which R_1 is hydrogen.


Claim 10 (amended) A compound of claim 1 in which R₂ is



Claim 11 (amended) A compound of claim 1 in which R₂ is




Claim 12 (amended) A compound of claim 1 in which R₂ is selected from the group consisting of



Claim 13 (amended) A compound of claim 1 selected from the group consisting of


- 1-[4-[(2-aminoethyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans-1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2(S)-aminopropyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2-aminoethyl)amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate and
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[3-[4-(pentyloxy)-phenyl]-1,2,4-oxadiazol-5-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate.

Claim 14 (amended) A process for the preparation of a compound of claim 1 reacting a compound of the formula



(II)


in which R, R₃, R₄, T, Y, W and Z are defined as in claim 1 with an amine or of an amine derivative capable of introducing



in which R1 and R2 are defined as in claim 1


and optionally then with a reducing agent,
and/or a functionalization agent of the amine,
and/or an acid to form the salt of the product of claim 1,
and/or a separation agent of the different isomers obtained.

Claim 15 (amended) A compound of the formula




wherein R, R₃, R₄, T, Y, W and Z are defined as in claim 1.

Claim 16 (amended) A process of claim 14 wherein a compound of the formula




R₃, R₄, T, W, Y and Z are defined as in claim 14 reacted with an agent capable of replacing -NH₂ by -NHR, R being defined as in claim 14 to obtain a compound of the formula



(IV)


reacting the said compound with trimethylsilyl iodide to obtain the corresponding compound of the formula




(II)

Cancel claims 17 to 19 and add the following claims.


Claim 20 (amended) A compound of claim 11 wherein R₂ is



Claim 21 (amended) A compound of the formula



or



(IV)

wherein R, R₃, R₄, T, W, Y and Z are defined as in claim 1.

22. An antifungal composition comprising an antifungally effective amount of a compound of claim 1 and in inert pharmaceutical carrier.

23. A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim 1.

REMARKS

The amendment is filed to insert reference to the PCT